Glutamine-regulated VCP acetylation creates a proteostasis vulnerability in RB1-deficient tumor
RB1 deficiency defines an aggressive tumor state with limited therapeutic options. Osteosarcoma represents a clinically relevant model of RB1 deficient malignancy, as RB1 alterations are among the most frequent genomic events in this tumor type. However, the non cell cycle vulnerabilities created by RB1 loss remain incompletely understood. We therefore used osteosarcoma to identify therapeutic…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
